Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3096-3104

  Fiskus, Warren ^a   Pranpat, Michael ^a   Balasis, Maria ^a   Herger, Bryan ^a   Rao, Rekha ^a   Chinnaiyan, Arul ^b   Atadja, Peter ^c   Bhalla, Kapil ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HUMAN ENHANCER OF ZESTE 2 PROTEIN; LBH 589; POLYCOMB REPRESSIVE COMPLEX 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA9 PROTEIN; TRANSCRIPTION FACTOR MEIS1 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

ACETYLATION; ACUTE DISEASE; CARRIER PROTEINS; CHRONIC DISEASE; DNA-BINDING PROTEINS; DOWN-REGULATION; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; K562 CELLS; LEUKEMIA; NUCLEAR PROTEINS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; U937 CELLS;

EID: 33846225576     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0418     Document Type: Article

References (49)

1. Mahmoudi T, Verrijzer CP. Chromatin silencing and activation by polycomb and trithorax group proteins. Oncogene 2001;20:3055-66.
2. Otte A, Kwaks THJ. Gene repression by polycomb group protein complexes: a distinct complex for every occasion? Curr Opin Genet Dev 2003; 13:448-54.
3. Jacobs JJ, van Lohuizen M. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002; 1602:151-61.
4. Valk-Lingbeek ME, Bruggerman SWM, van Lohuizen M. Stem cells and Cancer: the polycomb connection. Cell 2004; 118:409-18.
5. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and silencing function of the Eed/EZH2 complex. Mol Cell 2004; 15:57-67.
6. Hernandez-Munoz I, Taghavi P, Kuijl C, Neefjes J, van Lohuizen M. Association of BIVI1 with polycomb bodies is dynamic and requires PRC2/ EZH2 and the maintenance DNA methyltransf erase DNMT1. Mol Cell Biol 2005;25:11047-58.
7. Vire E, Brenner C, Deplus R, et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-4.
8. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T. The poiycomb-group gene EZH2 is required for early mouse development. Mol Cell Biol 2001;21:4330-6.
9. Erhardt S, Su IH, Schneider R, et al. Consequences of the depletion of zygotic and embryonic enhancer of zeste 2 during preimplantation mouse development. Development 2003; 130:4235-48.
10. Su I. Basavaraj A, Krutchinsky AN, et al. EZH2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 2003;4:124-31.
11. 27. Genes Dev 2004; 18:1592-605.
12. Montgomery ND, Yee D, Chen A, et al. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol 2005; 15:942-7.
13. Tonini T, Bagella L, D'Andrilli G, Claudio PP, Giordano A. EZH2 reduces the ability of HDACl-dependent pRIb2/p130 transcriptional repression of cyclin A. Oncogene 2004; 23:4930-7.
14. Pasini D, Bracken AP, Helin K. Polycomb group proteins in cell cycle progression and cancer. Cell Cycle 2004;3:396-400.
15. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268-73.
16. Kleer CG, Cao Q, Varambally S, at al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Aced Sci U S A 2003;100:11606-11.
17. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006; 12:1168-74.
18. Varambally S, Dhanasekaran SM, Zhou M, at al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9.
19. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation, and amplified in cancer. EMBO J 2003;22:5323-35.
20. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759-69.
21. Cha TL, Zhou BP, Xia W, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005;310: 306-10.
22. Visser HPJ, Gunster MJ, Kluin-Nelemans HC, at al. The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001;112:950-8.
23. Raaphorst FM, van Kemenade FJ, Blokzijl T, et al. Coexpression of Bmi-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000; 157:709-15.
24. van Kemenade FJ, Raaphorst FM, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001; 97:3896-901.
25. Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005;24: 6269-80.
26. Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A 2002;99:7622-7.
27. Iwasaki M, Kuwata T, Yamazaki Y, et al. Identification of cooperative genes for NUP98-9 in myeloid leukemogenesis using a mouse model. Blood 2005; 105:784-93.
28. Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. NUP98 - 9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J 2001;20:350-61.
29. Lawrence HJ, Rozenfeld S, Cruz C, et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 1999;13:1993-9.
30. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol 2001;21:224-34.
31. Wermuth PJ, Buchberg AM. Meis1-mediated apoptosis is caspase dependent and can be suppressed by co-expression of HoxA9 in murine and human cell lines. Blood 2005;105:1222-30.
32. Lawrence HJ, Fischbach NA, Largman C. HOX genes: not just myeloid oncogenes any more. Leukemia 2005;19:1328-30.
33. van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 1999;23:474-8.
34. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb EZH2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004; 18:2627-38.
35. Nimmanapalli R, O'Bryan E, Huang M, et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl positive, human acute leukemia cells retain sensitivity to SRC kinase inhibitor PD180970, and 17-allylamino-17-demethoxygeldanomycin (17AAG). Cancer Res 2002;62:5761-9.
36. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76.
37. Nimmanapali R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteosomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or-refractory chronic myelogenous leukemia blast crisis cells. Cancer Res 2003;63:5126-35.
38. Fiskus W, Pranpat M, Bali P, et al. Combined effects of novel tyrosine kinase inhibitor AMN 107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells. Blood. 2006;108: 645-52. Epub 2006 Mar 14.
39. Yoshida M, Kijma M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-9.
40. Guo F, Rocha K, Bali P, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005;65:10536-44.
41. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz 12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J 2004;23:4061-71.
42. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 2002;298:1039-43.
43. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004;14:155-64.
44. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006;20:1123-36.
45. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005;20:845-54.
46. Rossig L, Urbich C, Bruhl T, et al. Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells. J Exp Med 2005;201:1825-35.
47. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003;423:255-60.
48. Kamminga LM, Bystrykh LV, de Boer A, et al. The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 2006;107: 2170-9.
49. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971 -93.